What is the recommended initial dose of Vivitrol (extended‑release naltrexone) and what prerequisites (opioid‑free period, liver function) are required before administration?

Vivitrol Starting Dose

The recommended starting dose of Vivitrol is 380 mg administered as a deep intramuscular gluteal injection every 4 weeks (monthly), and patients must be opioid-free for a minimum of 7-10 days before the first injection to avoid precipitating severe opioid withdrawal. 1

Dosing Specifications

• Standard dose: 380 mg IM gluteal injection
• Frequency: Every 4 weeks (monthly)
• Administration site: Alternate buttocks with each subsequent injection
• Route: Must ONLY be administered as deep intramuscular gluteal injection using the customized needles provided in the carton 1

Critical Prerequisites Before First Dose

Opioid-Free Period

Patients must be completely opioid-free for 7-10 days minimum before initiating Vivitrol to avoid precipitating opioid withdrawal severe enough to require hospitalization 1. This applies to:

• Patients being treated for opioid dependence
• Patients being treated for alcohol dependence who may also use opioids 2

Verification Steps

• Confirm patient is not actively using opioids
• Consider naloxone challenge test if opioid use is uncertain
• Positive urine screen for opioids is a contraindication 1
• Patient should not be in acute opioid withdrawal at time of injection 1

Liver Function Monitoring

Obtain baseline liver function tests before initiating Vivitrol and monitor every 3-6 months during treatment 2. While the extended-release formulation avoids first-pass hepatic metabolism and appears safer than oral naltrexone, hepatotoxicity has been reported at supratherapeutic doses 2, 3.

Administration Technique Considerations

The needle length (1.5 or 2 inches provided) must be adequate for true intramuscular injection based on patient body habitus 1:

• Larger patients with more subcutaneous tissue: Use 2-inch needle to ensure medication reaches muscle
• Very lean patients: 1.5-inch needle may be appropriate to avoid periosteal contact
• Average body habitus: Either needle acceptable
• If proper IM injection cannot be achieved with provided needles, consider alternate treatment 1

Special Populations

Alcohol Dependence

Patients must be able to abstain from alcohol in an outpatient setting prior to initiation and should not be actively drinking at time of first injection 1

Opioid Dependence

Vivitrol is indicated for prevention of relapse following opioid detoxification—not for active detoxification 1

Critical Safety Warnings

At each injection visit, counsel patients about opioid overdose risk and strongly consider prescribing/recommending an opioid reversal agent (naloxone or nalmefene) 1. Patients are vulnerable to potentially fatal overdose:

• At the end of the dosing interval (near end of month)
• After missing a dose
• After discontinuing treatment
• Because opioid tolerance is reduced from baseline 1

Common Pitfalls to Avoid

1. Do not skip the opioid-free waiting period—precipitated withdrawal can be severe and require hospitalization 1
2. Do not use oral naltrexone pretreatment—it is not required before Vivitrol 1
3. Do not administer subcutaneously or IV—must be deep IM gluteal only 1
4. Do not use non-customized needles—only use needles provided in carton 1

Perioperative Management

If surgery requiring opioid analgesia is planned, intramuscular naltrexone should be held 24-30 days after the last injection (oral naltrexone 3-4 days) 4. The long-acting formulation creates prolonged opioid receptor blockade that can complicate pain management.

Comprehensive Management

Vivitrol must be part of a comprehensive management program including psychosocial support 2, 1. The medication alone is insufficient—behavioral therapies and counseling are essential components of treatment.